Arch Biopartners Inc. (ACHFF)
OTCMKTS · Delayed Price · Currency is USD
0.6067
+0.0267 (4.60%)
Sep 28, 2026, 3:42 PM EST
Arch Biopartners Market Cap
Arch Biopartners has a market cap or net worth of $41.22 million as of September 28, 2026. Its market cap has decreased by -37.90% in one year.
Market Cap
41.22M
Enterprise Value
43.13M
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
$0.61
ChartMarket Cap Chart
Since January 21, 2011, Arch Biopartners's market cap has increased from 33.63M to 41.22M, an increase of 22.57%. That is a compound annual growth rate of 1.31%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 28, 2026 | 41.22M | -30.30% |
| Dec 31, 2025 | 59.13M | -32.56% |
| Dec 31, 2024 | 87.67M | 25.12% |
| Dec 29, 2023 | 70.07M | -46.02% |
| Dec 30, 2022 | 129.79M | -23.83% |
| Dec 31, 2021 | 170.40M | 138.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 26, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 26, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| NDT Pharmaceuticals | 76.02M |
| Nuo Therapeutics | 60.54M |
| Sangamo Therapeutics | 59.66M |
| Biomind Labs | 35.68M |
| ProText Mobility | 31.65M |
| Cell Source | 28.50M |
| Vicapsys Life Sciences | 25.41M |
| Provectus Biopharmaceuticals | 22.91M |